119 completed, 25 unknown, 20 terminated, 8 recruiting. 79 Phase 2, 37 Phase 1, 36 Phase 3, 31 Not applicable, 23 Phase 4.
Follow N-Acetylcysteine: new trials by email Literature Review of N-Acetylcysteine trials Research Report on N-Acetylcysteine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Tolerability of Enteral NAC in Infants N-Acetylcysteine - Biliary Atresia | Phase 1 | Not yet recruiting | Sanjiv Harpavat | 12 | 2026-10-01 | 2026-03-04 |
| Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients N-acetylcysteine - Aplastic Anemia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 142 | 2026-09-30 | 2026-09-16 |
| Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease Muco-active agents, No muco-active agent use - Lung Cancer (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD) | Active not recruiting | Seoul National University | 27000 | 2026-06-01 | 2026-07-21 | |
| Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth N-acetylcysteine, Mindfulness-based cognitive therapy, Placebo - Mild Depression | Phase 3 | Recruiting | University of Cincinnati | 160 | 2026-02-26 | 2026-03-11 |
| N-Acetylcysteine in Patients With Leptospirosis N-acetylcysteine, Placebo - Leptospirosis | Phase 2 | Completed | Dr Cipto Mangunkusumo General Hospital | 64 | 2025-08-30 | 2026-09-16 |
| A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine N-Acetylcysteine - Psychosis | Phase 4 | Not yet recruiting | National Taiwan University Hospital | 20 | 2024-08-01 | 2024-08-09 |
| A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers NAC, Placebo - Huntington Disease | Phase 2 | Recruiting | Western Sydney Local Health District | 160 | 2024-06-01 | 2025-02-28 |
| Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients Syrup Prospan, N-Acetylcysteine - Chronic Obstructive Pulmonary Disease | Not applicable | Recruiting | National University of Malaysia | 100 | 2024-05-01 | 2025-11-19 |
| NAC for Attenuation of COVID-19 Symptomatology N-acetylcysteine, Placebo - Covid19, COVID-19 Pneumonia | Phase 2 | Unknown | Cambridge Health Alliance | 200 | 2024-03-31 | 2023-08-07 |
| Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label N-acetylcysteine - Autism Spectrum Disorder | Phase 2 / Phase 3 | Enrolling by invitation | Stanford University | 144 | 2024-03-12 | 2026-05-15 |
| Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice N-acetylcysteine - Hepatic and Post Hepatic Jaundice | Phase 2 | Completed | Tanta University | 44 | 2024-02-14 | 2026-07-22 |
| Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study Aspirin 81Mg Ec Tab, Clopidogrel, N-acetylcysteine - Dry Age-related Macular Degeneration | Phase 3 | Unknown | Navamindradhiraj University | 174 | 2023-12-01 | 2023-12-15 |
| Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke Acetylcysteine, Dextrose in Water - Acute Ischemic Stroke | Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 4 | 2023-11-02 | 2026-02-19 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD N-acetylcysteine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Unknown | Queen Mary Hospital, Hong Kong | 80 | 2023-09-18 | 2023-11-18 |
| Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity N-Acetylcysteine, Chemotherapy - Drug Toxicity | Not applicable | Unknown | Foundation University Islamabad | 70 | 2023-08-09 | 2023-08-31 |
| Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels N-Acetylcysteine - Mitochondrial Disease | Phase 1 | Recruiting | Michio Hirano, MD | 18 | 2023-07-06 | 2026-01-23 |
| A Study of NAC for AUD N-acetylcysteine, Placebo - Alcohol Use Disorder | Phase 2 | Withdrawn | Uniformed Services University of the Health Sciences | 2023-04-01 | 2023-07-21 | |
| Effects of NAC on Symptoms of CHR Patients N-Acetylcysteine, Placebo - Prodromal Schizophrenia | Not applicable | Recruiting | Centre for Addiction and Mental Health | 90 | 2023-01-13 | 2026-03-27 |
Showing 20 of 191. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (9) · Renal Insufficiency, Chronic (8) · Acute Kidney Injury (7) · COVID-19 (7) · Cocaine-Related Disorders (7) · Schizophrenia (7) · Inflammation (6) · Kidney Failure, Chronic (6) · Alcoholism (5) · Marijuana Abuse (5) · Psychotic Disorders (5) · Renal Insufficiency (5) · Autism Spectrum Disorder (4) · Bipolar Disorder (3) · Bronchitis, Chronic (3)
Medical University of South Carolina (12) · Yale University (7) · University of Minnesota (5) · Assaf-Harofeh Medical Center (3) · Baylor College of Medicine (3) · Memorial Sloan Kettering Cancer Center (3) · Stanford University (3) · Bloodworks (2) · Cambridge Health Alliance (2) · Ewha Womans University (2) · Indiana University (2) · Minneapolis Veterans Affairs Medical Center (2) · TC Erciyes University (2) · University of California, San Francisco (2) · University of Michigan (2)
United States (85) · Brazil (11) · Canada (10) · United Kingdom (8) · Belgium (7) · Netherlands (6) · Germany (5) · Italy (5) · Spain (5) · Australia (4) · China (4) · Egypt (4) · France (4) · Greece (4) · Indonesia (4)
Kevin M Gray, MD (4) · Edward A Neuwelt, MD (2) · John Hegarty, PhD (2) · A C Abrahams, MD (1) · Abdias Hurtado, MD (1) · Abraham IJ Gajardo, MD, PhD (1) · Alexandre Danilovic, MD (1) · Alfredo Aisa Alvarez, MD (1) · Ali J. Marian, MD (1) · All Validations Passed Badran, PhD (1) · Andras Perl, M.D., Ph.D. (1) · Andreas Zollinger, MD (1)
PMID 37916745, PMID 23860343, PMID 16306520, PMID 16443707, PMID 17606664, PMID 18202091, PMID 18295688, PMID 18434903, PMID 18513531, PMID 19384218, PMID 19554195, PMID 19563648, PMID 19860915, PMID 20541301, PMID 20956181, PMID 21551083, PMID 22549432, PMID 23219310, PMID 23265409, PMID 23452680, PMID 23452681, PMID 24293993, PMID 24988878, PMID 25064164, PMID 25073872, PMID 25148231, PMID 25250647, PMID 25384603, PMID 26139231, PMID 26151174, PMID 26301645, PMID 26503312, PMID 26545726, PMID 26922582, PMID 27143871, PMID 27411777, PMID 27736051, PMID 28623823, PMID 28847455, PMID 29130810, PMID 29391265, PMID 29540445, PMID 29619634, PMID 29970108, PMID 30176835, PMID 30415748, PMID 30621764, PMID 30975143, PMID 31077039, PMID 31107966
K99HD101702 (2), U54NS065768 (2), 1UG1EY033293 (1), I01CX000264 (1), K01DA039299 (1), K12DA000357 (1), K23AA025399 (1), P01HL128191 (1), P30CA015083 (1), P50DA015369 (1), P50DA046373 (1), R01AA025365 (1), R01AT013115 (1), R01DA019903 (1), R01DA026777 (1)